MannKind Corp. (MNKD)

[purdue pete]

"Lantus, which lost patent protection earlier this year, saw overall sales drop 11 percent at constant currencies as Eli Lilly & Co. introduced a cheaper generic rival in Europe. In the U.S., where revenue slid 20 percent, Sanofi was forced to offer insurers bigger rebates, it sold more to government channels such as Medicaid and found that demand for injected insulin overall had weakened as more patients turned to new oral alternatives."

Injected insulin is weakening....sounds good for inhaled.....